Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
In Vitro Diagnostics (IVD) Quality Control Market
The global In Vitro Diagnostics (IVD) Quality Control market is positioned for steady expansion from 2025 to 2035, driven by increasing demand for accurate diagnostic tools and stringent regulatory compliance across healthcare systems. The market, valued at USD 1.48 billion in 2025, is projected to reach USD 2.49 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.3%. Quality control solutions in plasma, whole blood, and urine matrices remain foundational to laboratory operations, ensuring the reliability of immunoassay, hematology, microbiology, and molecular diagnostics workflows.
End-user adoption is broad, spanning hospitals, clinical laboratories, academic institutions, and public health entities, with growth catalyzed by technological advancements and the rising prevalence of chronic and infectious diseases.
Market size
Growth trajectory through 2035
In Vitro Diagnostics (IVD) Quality Control Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2025 Product Launches
- In 2025, several manufacturers introduced next-generation quality control materials designed for molecular diagnostics, addressing the growing demand for genetic and viral testing accuracy.
-
Development 02 Regulatory Updates
- New guidelines from the FDA and EU IVDR have prompted manufacturers to update their quality control portfolios to ensure compliance with updated standards.
-
Development 03 Partnerships
- Collaborations between IVD manufacturers and quality control providers aim to integrate automated workflows with advanced analytics, improving turnaround times and reducing operational costs.
-
Development 04 Market Expansion
- Companies are increasingly targeting emerging markets through localized manufacturing and distribution partnerships to capitalize on growing healthcare investments.
Emerging opportunities added
- Emerging Markets Growth Expansion into Asia-Pacific, Latin America, and the Middle East offers significant growth potential due to improving healthcare infrastructure and rising disease prevalence.
- Digital Transformation Adoption of AI-driven analytics and cloud-based quality management systems presents opportunities for enhanced data integrity and operational efficiency.
- Partnerships and Collaborations Strategic alliances between IVD manufacturers, quality control providers, and academic institutions can accelerate innovation and market penetration.
- Customized Solutions Development of matrix-specific and disease-focused quality control materials tailored to regional or institutional needs can capture niche market segments.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $1.48 Bn
- CAGR
- 5.30%
- Expansion
- 1.7×
Market shape
leading region
- Leading region
- North America
- Top end-user
- Hospitals
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High Cost of Implementation
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Product Launches: In 2025, several manufacturers introduced next-generation quality control materials designed for molecular diagnostics, addressing the growing demand for genetic and viral testing accuracy
+3 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 178-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the In Vitro Diagnostics (IVD) Quality Control Market today ($1.48 Bn base), and how fast will it grow at 5.3% CAGR through 2035?
- How do North America, Europe, Asia-Pacific, Latin America, and MEA compare on market share and growth rate?
- Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Regulatory Compliance) and top restraints (led by High Cost of Implementation), with quantified CAGR impact?
- What regulatory shifts and 4 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Regulatory Compliance Increasing emphasis on ISO 15189, CLIA, and other quality standards drives demand for certified IVD quality control materials.
- Technological Advancements Integration of automation and digital platforms enhances workflow efficiency and reduces human error in diagnostic testing.
- Rising Chronic Disease Burden Growth in diabetes, cardiovascular diseases, and oncology necessitates reliable diagnostic tools, thereby increasing the need for quality control solutions.
- Expansion of Point-of-Care Testing Decentralization of diagnostic testing increases the requirement for standardized quality control measures across diverse testing environments.
- Public Health Initiatives Global health programs focused on infectious disease surveillance and pandemic preparedness drive adoption of validated IVD quality control systems.
Restraints
Holding it back
- High Cost of Implementation Initial investment in quality control systems and compliance infrastructure can be prohibitive for smaller laboratories and emerging markets.
- Supply Chain Vulnerabilities Dependence on specialized reagents and materials exposes the market to disruptions in global supply chains, particularly for high-demand diagnostic components.
- Regulatory Complexity Variability in regional regulatory requirements creates operational challenges for manufacturers and laboratories seeking to maintain compliance across multiple jurisdictions.
- Limited Awareness in Emerging Markets In certain regions, limited understanding of the importance of quality control in IVD testing may slow adoption rates.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Regulatory Compliance | +2.4% | Global | 2025–2035 |
| Technological Advancements | +1.5% | Global | 2025–2035 |
| Rising Chronic Disease Burden | +1.2% | Global | 2025–2035 |
| Expansion of Point-of-Care Testing | +0.8% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High Cost of Implementation | −1.0% | Global | 2025–2029 |
| Supply Chain Vulnerabilities | −0.6% | Global | 2025–2029 |
| Regulatory Complexity | −0.5% | Global | 2025–2029 |
The IVD Quality Control market is segmented by Source, Technology, and End User.
By technology
-
biomarker testing. Hematology
-
microbiology
-
cellular analysis
By end-user industry
-
Hospitals
-
clinical laboratories represent the largest share
-
driven by high test volumes
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $1.48 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~40.0% in 2025. Driven by manufacturing scale and end-market density.
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The IVD Quality Control market is moderately consolidated, with a mix of multinational corporations and specialized providers competing across product segments. Leading players such as Roche Diagnostics, Abbott, Bio-Rad Laboratories, and Thermo Fisher Scientific dominate due to their extensive portfolios, global distribution networks, and strong brand recognition. Smaller firms and regional players focus on niche applications, such as matrix-specific or disease-targeted controls, to differentiate their offerings. Competitive strategies include mergers and acquisitions to expand product lines, strategic collaborations with diagnostic laboratories, and investments in digital quality management platforms to enhance customer engagement and operational efficiency.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Thermo Fisher Scientific
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Danaher Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Diagnostics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Diagnostics
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Bio-Rad Laboratories
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
QIAGEN N.V
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the worth of global in-vitro diagnostic (IVD) quality control market?
The in-vitro diagnostic (IVD) quality control market size had crossed USD 1.04 Billion in 2020 and will observe a CAGR of more than 5.3 % up to 2029 driven by the implementation of quality assurance programs in various medical disciplines, including radiology and point-of-care (PoC) devices, is necessitated by the constantly evolving technological-oriented changes in the diagnostics field, as well as the growing need to ensure patient safety. -
• What is the size of the North America in-vitro diagnostic (IVD) quality control industry?
North America held more than 36% of the in-vitro diagnostic (IVD) quality control market revenue share in 2020 and will witness expansion with the high adoption rate of advanced infrastructure, an increase in the number of diagnostic centers, and accredited clinical laboratories. -
• Which is the leading product segment in IVD quality control devices market?
The IVD quality control market is divided into three segments based on product and service: quality control products, data management solutions, and quality assurance services. In 2020, the quality control products segment held the largest share of the IVD quality control market. The growing number of accredited laboratories, as well as regulatory bodies' mandates for the use of quality controls to ensure the accuracy of diagnostic test results, are driving the growth of the IVD quality control products market. -
• Which are the top companies to hold the market share in in-vitro diagnostic (IVD) quality control market?
Key players profiled in the report include Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Randox Laboratories Ltd., Roche Diagnostics, Abbott Diagnostics, Helena Laboratories, Seracare Life Sciences, Inc., Technopath Clinical Diagnostics, and Sun Diagnostics, LLC. -
• What is the leading application of IN-VITRO DIAGNOSTIC (IVD) QUALITY CONTROL market?
Molecular diagnostics is expected to witness the highest growth in the IVD quality control market. In the ongoing COVID-19 pandemic, molecular diagnostic tests have been used widely across the globe. PCR tests for COVID-19 are used to diagnose people who are currently infected with SARS-CoV-2. PCR is the “gold standard” test for diagnosing COVID-19 because it is the most accurate and reliable test. The increasing number of positive cases, increasing awareness. -
• Which is the largest regional market for in-vitro diagnostic (IVD) quality control market?
North America is expected to dominate the global market for In Vitro Diagnostics quality controls. The market in the region is expected to be fueled by a high rate of adoption of advanced infrastructure, as well as an increase in the number of diagnostic centers and accredited clinical laboratories. The United States has the largest market share in North America due to its larger patient pool.
The In Vitro Diagnostics (IVD) Quality Control Market is projected to reach $2.48 Bn by 2035, up from $1.48 Bn in 2025 — a 5.30% CAGR equating to roughly 1.7× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.